Comparative Effectiveness, Generic Biologics Draw Insurers’ Lobbying Efforts

Comparative effectiveness research and generic biologics are among the key pharmaceutical issues that attracted lobbying efforts by large health insurers in the first half of 2007, according to reports filed recently with Congress